Fisher Center Discovery Program (FCDP)

Fisher Center Discovery Program

To develop excellence in clinical research regarding environmental infectious pathogens, the Center has created the Fisher Center Discovery Program (FCDP).  Goals of the FCDP include:

  • Funding of grants for clinical research related to environmental infectious diseases
  • Provision of resources for studies that lack traditional funding mechanisms
  • Promotion of cross-disciplinary collaborative research
  • Provision of mentoring opportunities for early career investigators

We award a maximum of $60,000 to individual Johns Hopkins researchers during a single annual grant cycle.  Notifications about the grants opportunity are distributed by email via individual schools of the Johns Hopkins University and pertinent faculty list serves.  All full-time faculty members of the Johns Hopkins University, especially junior faculty, are encouraged to apply. For questions concerning the grants program, please email or call 443-287-4800.

These Discovery Program grants are possible through the generous support of Sherrilyn Fisher.

2022 Fisher Center Discovery Program Grant Cycle

Important Changes for the 2022 Grant Cycle

For the previous grant cycle (2021), we accepted proposals related to COVID-19 and SARS-CoV-2.  Please note, for this current grant cycle (2022), the FCDP will revert to its original focus on clinical and translational research related only to environmental infectious diseases.  However, proposals with both a COVID-19/SARS-CoV-2 and environmental focus (e.g., built environments, environmental transmission) will be considered.  Basic laboratory research proposals will not be reviewed. Laboratory-based research will only be considered if it relates directly to clinical or translational research.

If you have questions regarding whether a COVID-19/SARS-CoV-2 and environmental infectious diseases proposal would be appropriate for the Fisher Center Discovery Program, please submit a Letter of Intent (form below)


Applicants are strongly encouraged to review the document FCDP Application Guidelines 2022 before completion of the proposal and application.

Letter of Intent submission deadline Monday, October 4, 2021. Form provided below.

Full Application submission deadline Monday, October 25, 2021 at 11:59 PM. Form provided below.

Award notice on or before November 30, 2021.

FCDP Timeline 2022

To Apply

  • On or before October 25, 2021 submit these documents via email,
  • Save all documents as individual documents.  Do not combine documents.
  • The complete application package is composed of the following documents.

Documents to submit in the application package:

  • FCDP Application Form 2022, provided below
  • Protocol: abstract; background; objectives; methods; timeline; proposal benefits; endnotes
  • Biosketch, Curriculum Vitae, or résumé of 1) The PI 2) Co-investigators 3) Staff receiving salary support, saved as individual files
  • Letter of support from the Faculty preceptor for applicants who are not JHU faculty
  • Letters of support from collaborators and research partners (optional, but encouraged), saved as individual files
  • Budget – use template provided below
  • Written justification of salary requests exceeding 50% of the monetary award, if necessary
  • Written justification of laboratory supplies, equipment, and service requests exceeding 50% of the monetary award, if necessary

    2022 Document Library
    FCDP Request for Application 2022
    FCDP Application Guidelines 2022
    FCDP Frequently Asked Questions 2022
    FCDP Letter of Intent Form 2022
    FCDP Application 2022
    FCDP Budget Template 2022

    FCDP Prior Awarded Projects

    Principal Investigators were Johns Hopkins University faculty at the time of award. Co-investigators are not listed.

    YearPrincipal InvestigatorProject Title
    2021Netz Arroyo, PhDPoint-of-need platform for population-scale monitoring of SARS-CoV-2 neutralizing antibodies
    2021Challice Bonifant, MD PhDH84T-BanLec CAR-NK Cells as Treatment for SARS-CoV-2 Infection
    2021Karen Carroll, MD
    Next Generation Sequencing for Pathogen Identification in Lower Respiratory Infections
    2021Meghan Frost Davis, DVM, MPH PhDImmunologic markers associated with environmental exposure to enterotoxin-producing Staphylococcus aureus
    2021Maged Mohamed Harraz, MBBCh, MSc, PhDAutophagic degradation of ACE2 as a Therapeutic Target in Covid-19
    2021Nitipong “Nate” Permapalung, MD, MPHOptimizing Diagnostics for Environmentally Acquired Fungal Pneumonia Complicating COVID-19
    2021Matthew Robinson, MDA comprehensive suite of web tools to predict COVID-19 trajectory
    2021Maxim Rosario, D.Phil., MB BCH BAO, MSc PhDAdoptive NK cell Therapy for Acquired Fungal Infection
    2020Keira Cohen, MDEarly bactericidal activity of standard drugs used to treat Mycobacterium avium complex: a pilot study
    2020Gyanu Lamichhane, PhDDeveloping antibiotic regimen to treat M. abscessus disease based on whole genome mining
    2020Michael Melia, MDBeta-d-glucan and galactomannan curriculum
    2020Heba Mostafa, MD, PhDGenomic Surveillance of Enteroviruses' Polymorphic Events that Correlate with Disease Severity and Neuro-virulence
    2020David Sullivan, MDMurine Babesia Combination Chemotherapy
    2020Sean Zhang, MD, PhDPOC.auris: A 15-minute point-of-care detection of multi-drug resistant Candida auris
    2018Anthony K. L. Leung, PhDUnderstanding how virus virulence is regulated by the ADP-ribosylhydrolase activity of the macrodomain - a potential drug target
    2018Kimberly M. Davis, PhDThe role of amoebae in enhancing the virulence of environmental human pathogens
    2018Brian Garibaldi, MDEnvironmental transmission and traceability of aerosolized bio-stimulants in a clinical biocontainment unit
    2017Keeve Nachman, PhDBuilding a baseline for assessing the human health impact of a landmark legislative intervention on antibiotic use in industrial poultry production
    2017Sabra L. Klein, PhDIdentification of early detection biomarkers and candidate therapeutics for congenital Zika virus infection
    2017Evan Bloch, MBChB, MD, MSAfrican BAOBAB (Babesia Observational Antibody) Study
    2017Aaron Milstone, MDImpact of Heterogeneous Resistance Mechanisms on Hospital Transmission of Carbapenem-Resistant Enterobacteriaceae (CRE)
    2016Petros Karakousis, MDIdentifying molecular targets for preventing multidrug tolerance in Mycobacterium avium infection
    2016Diane Griffin, MD, PhDThe role of nsP3 in neurovirulence of chikungunya virus
    2016Patricia Simner, MSc, PhDMolecular Epidemiology of Carbapenem Resistant Gram-Negative Organisms (CROs) at Johns Hopkins Hospital: Do Patients Infected with CROs Contaminate the Hospital Room Environment?
    2016Brian Schwartz, MD, MSHigh-density poultry operations and associated infectious disease risks
    2015Kieren Marr, MDDiagnostics for latent histoplasmosis
    2015Trish Perl, MD At UT SW since 2016.The Home Environment: Infections among Patients Discharged Home with Venous Catheters
    2015Margaret Kosek, MD. At UVA since 2019.Salivary diagnostics for pathogens of clinical significance in childhood environmental enteropathy
    2014Pranita Tamma, MD, MHSAn evidence-based screening approach to identify children at high risk for harboring multi-drug resistant Gram-negative organisms in the PICU
    2014Elizabeth Matsui, MD, MHS At UT Austin since 2018.Home Environmental Exposure to Staphylococcal Bacteria and Asthma Exacerbation
    2014Christine Marie George, PhDIdentifying Environmental Transmission Routes for Shigellosis in Rural Settings using Pulsed-field Gel Electrophoresis
    2014Mark Soloski, PhDImmune Events in Human Lyme Disease
    2014Nicole Parrish, PhDCharacterization of β-lactam Resistance in Enterobacteriaceae Isolated from the Chesapeake Bay and Upper Watershed
    2014Priya Duggal, PhD, MPHHost Genetic Susceptibility to Cryptosporidia Infection
    2013Aaron Milstone, MD, MHSDevelopment and Clinical Evaluation of Laboratory Methods to Identify Reduced Antiseptic Susceptibility in Organisms Causing Healthcare Associated Infections
    2013Megan Reller, MD, MPH At Duke since 2016.Detection of Unrecognized Tick-borne Febrile illness in the Upper Midwest and Northeast United States
    2013Trish Perl, MD At UT SW since 2016.Clostridium difficile: Impact of colonization versus transmission on development of infection
    2013Cynthia Sears, MDDoes Disruption of Host Microbiota Modify Colorectal Cancer Risk?
    2013Christopher Heaney, PhDEvolutionary dynamics of multidrug-resistant Staphylococcus aureus (MDRSA), a zoonotic pathogen of clinical significance, among industrial food animal production workers